RedShift BioAnalytics

OverviewSuggest Edit

RedShift BioAnalytics is developing powerful new analytical tools for the R&D, life science and biopharmaceutical markets. Our measurement solutions combine tunable lasers, microfluidics, and analytical technologies to achieve revolutionary improvements in performance and measurement capabilities. 
RedShift BioAnalytics has developed a powerful new analytical technique called Microfluidic Modulation System, or MMS, that at long last enables the optical detection of very low levels of analytes in fluids. When applied to the detection of protein therapeutics, MMS provides the direct measurement, at the native concentrations, of a protein’s underlying biophysical structures. By harnessing the optical power and tunability of lasers, and the precision of fluidic modulation, MMS can rapidly measure a protein sample and its reference buffer in a single microfluidic cell.
At RedShift, our mission is to provide customers with solutions that accelerate product discovery, development and manufacturing timelines while enabling dramatic improvements in performance, efficiency and cost.

HQBurlington, US

Latest Updates

Employees (est.) (Jun 2020)30(+16%)
Cybersecurity ratingAMore

Key People/Management at RedShift BioAnalytics

Julien Bradley

Julien Bradley

Chief Executive Officer
Eugene Ma

Eugene Ma

Chief Technology Officer
Chip Marshall

Chip Marshall

Chief Operating Officer
Richard Sharp

Richard Sharp

VP of Engineering
Jeffrey Zonderman

Jeffrey Zonderman

Chief Commercial Officer
Show more

RedShift BioAnalytics Office Locations

RedShift BioAnalytics has an office in Burlington
Burlington, US (HQ)
131 Middlesex Turnpike
Show all (1)

RedShift BioAnalytics Financials and Metrics

Summary Metrics

Founding Date


RedShift BioAnalytics total Funding

$27.8 m

RedShift BioAnalytics latest funding size

$11 m

Time since last funding

3 years ago

RedShift BioAnalytics investors

RedShift BioAnalytics's latest funding round in March 2017 was reported to be $11 m. In total, RedShift BioAnalytics has raised $27.8 m
Show all financial metrics

RedShift BioAnalytics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

RedShift BioAnalytics Online and Social Media Presence

Embed Graph

RedShift BioAnalytics Blogs

Inspiring innovative biotherapeutic protein drug development at PEGS 2019

One year on from introducing the AQS3TMpro, a powerful new protein characterization solution, we demonstrated compelling new application data and significant endorsements from leading biopharmaceutical companies at PEGS 2019. Driven by industry-leading AQS3delta analytical software, the AQS3pro is t…

Scientists See Change in Higher Order Structure with MMS, at HOS 2019

HOS 2019 highlighted the range of biophysical characterization methods and tools used in monitoring the attributes of protein therapeutics such as conformation and higher order structure. We showcased AQSpro with Microfluidic Modulation Spectroscopy (MMS), a system that addresses the limitations of …

Higher Order Structure: The Hot Topic of Biotherapeutics Analytical Summit

We have just returned from the Biotherapeutics Analytical Summit in Virginia. What a great celebration of the conference’s 10th birthday! We were inundated with fascinating conversations, the most popular being the characterization of higher order structure (or HOS). We presented a poster with Elion…

RedShiftBio Joined Thought Leaders at Biotherapeutics and Vaccines Development (Gordon Research Conference)

Critical Quality Attributes to Advance Therapeutics and Vaccines from Candidate Selection to Drug Product Biotherapeutics and vaccines are critical in improving public health. They are being developed for acute and chronic clinical indications that cover the spectrum from infectious diseases to onco…

RedShiftBio Shines at PepTalk 2019

We were excited to exhibit at PepTalk 2019 for the first time. PepTalk: The Protein Science Week is one of the largest annual gatherings of protein science researchers in the world. The international delegation of over 1,300 participants attended for intensive learning and networking to discover new…

AQS3pro: a cutting edge addition to the bioanalytical technologies showcased at WCBP 2019

The WCBP Symposium series was created to address issues at the interface of analytical development and global regulatory for biotechnology-derived health intervention products. The goal was to provide a forum for discussing the latest bioanalytical methods and their practical application to biotechn…
Show more

RedShift BioAnalytics Frequently Asked Questions

  • When was RedShift BioAnalytics founded?

    RedShift BioAnalytics was founded in 2005.

  • Who are RedShift BioAnalytics key executives?

    RedShift BioAnalytics's key executives are Julien Bradley, Eugene Ma and Chip Marshall.

  • How many employees does RedShift BioAnalytics have?

    RedShift BioAnalytics has 30 employees.

  • Who are RedShift BioAnalytics competitors?

    Competitors of RedShift BioAnalytics include Halo Labs, China Pharma Holdings and ImmuCell.

  • Where is RedShift BioAnalytics headquarters?

    RedShift BioAnalytics headquarters is located at 131 Middlesex Turnpike, Burlington.

  • Where are RedShift BioAnalytics offices?

    RedShift BioAnalytics has an office in Burlington.

  • How many offices does RedShift BioAnalytics have?

    RedShift BioAnalytics has 1 office.